Downregulatory cytokines in tracheobronchial aspirate fluid from infants with chronic lung disease of prematurity

被引:43
|
作者
Jónsson, B [1 ]
Li, YH
Noack, G
Brauner, A
Tullus, K
机构
[1] Karolinska Hosp, Astrid Lindgrens Childrens Hosp, Dept Neonatol, SE-17176 Stockholm, Sweden
[2] Karolinska Hosp, Astrid Lindgrens Childrens Hosp, Dept Pediat Anaesthesiol, Stockholm, Sweden
[3] Karolinska Hosp, Astrid Lindgrens Childrens Hosp, Dept Pediat, Stockholm, Sweden
[4] Karolinska Hosp, Dept Clin Microbiol, Stockholm, Sweden
关键词
preterm; chronic lung disease; tracheobronchial aspirate fluid; transforming growth factor-beta 1; interleukin-10; interleukin-4; interleukin-12;
D O I
10.1080/080352500300002606
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Chronic lung disease of prematurity (CLD) is associated with an inflammatory response in the preterm lung and increased levels of proinflammatory cytokines in tracheobronchial aspirate fluid (TAF). We investigated TAF levels of transforming growth factor-beta1(TGF-beta1), interleukin-10 (IL-10), interleukin-4 (IL-4) and interleukin-12 (IL-12) cytokines possibly important in downregulating the proinflammatory response and/or inducing lung fibrosis in infants with developing and established CLD. Infants with CLD (n = 24) were compared with preterm infants with RDS that resolved (n = 22) and postoperative infants without lung disease (n = 23). TAF levels of TGF-beta1, IL-10, IL-4 and IL-12 were studied by quantitative enzyme immunoassay. Levels of TGF-beta1 were significantly higher during the first week of life in infants who developed CLD, remained high at 2 wk and past 4 wk of age. TAF levels of TGF-beta1 did not decrease significantly in six infants with CLD after treatment with steroids. TAF IL-10 was detected in 12/46 (26%) preterm infants. Infants with CLD or RDS were more likely to have measurable TAF levels of IL-10, compared with the postoperative infants without lung disease (p < 0.02 and 0.04, respectively). TAF levels of IL-4 or IL-12 were below the detection limits in all samples. Conclusions: We have demonstrated a sustained increase of TGF-<beta>1 levels in TAF from preterm infants who develop CLD, suggesting an important role for TGF-beta1 in the fibrotic response in the CLD lung. The elevated TGF-beta1 levels, combined with an absent or irregular secretion of IL-4, IL-10 and IL-12, can have importance for the increased tendency for the development of CLD in preterm infants.
引用
收藏
页码:1375 / 1380
页数:6
相关论文
共 50 条
  • [31] CHRONIC LUNG-DISEASE OF PREMATURITY
    SCHICK, JB
    GOETZMAN, BW
    PEDIATRICS, 1985, 76 (04) : 652 - 652
  • [32] Diuretics and Chronic Lung Disease of Prematurity
    Luc P Brion
    Sin Chuen Yong
    Iris A Perez
    Robert Primhak
    Journal of Perinatology, 2001, 21 (5) : 269 - 271
  • [33] Fluid restriction for treatment of preterm infants with chronic lung disease
    Barrington, Keith J.
    Fortin-Pellerin, Etienne
    Pennaforte, Thomas
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (02):
  • [34] TRACHEOBRONCHIAL CLEARANCE IN CHRONIC OBSTRUCTIVE LUNG DISEASE
    LOURENCO, RV
    ANDERSON, TO
    LEVINE, H
    JOURNAL OF CLINICAL INVESTIGATION, 1969, 48 (06): : A53 - &
  • [35] Elevated tracheal aspirate hyaluronic acid concentrations in preterm infants developing chronic lung disease
    Savani, RC
    Banks, BA
    Ballard, RA
    Coburn, C
    Cnaan, A
    Pooler, PM
    Godinez, MH
    Godinez, RI
    Ballard, PL
    JOURNAL OF INVESTIGATIVE MEDICINE, 2000, 48 (02) : 213A - 213A
  • [36] Azithromycin resistance in the stool of preterm infants at risk of chronic lung disease of prematurity (CLD)
    Course, C.
    Gallacher, D.
    Aboklaish, A.
    Zhang, L.
    Marchesi, J.
    Kotecha, S.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [37] THE ACUTE RESPONSE TO DEXAMETHASONE THERAPY IN INFANTS WITH CHRONIC LUNG-DISEASE (CLD) OF PREMATURITY
    NAGOURNEY, BA
    DAVIS, GM
    USHER, RH
    PEDIATRIC RESEARCH, 1990, 27 (04) : A217 - A217
  • [38] Study protocol: azithromycin therapy for chronic lung disease of prematurity (AZTEC)-a randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants
    Lowe, John
    Gillespie, David
    Hubbard, Marie
    Zhang, Lei
    Kirby, Nigel
    Pickles, Timothy
    Thomas-Jones, Emma
    Turner, Mark A.
    Klein, Nigel
    Marchesi, Julian R.
    Hood, Kerenza
    Berrington, Janet
    Kotecha, Sailesh
    BMJ OPEN, 2020, 10 (10):
  • [39] Lung development is impaired in chronic lung disease of prematurity
    Albertine, KH
    Pierce, RA
    Starcher, BC
    MacRitchie, AN
    Carlton, DP
    Bland, RD
    FASEB JOURNAL, 1999, 13 (05): : A1154 - A1154
  • [40] Lack of effect of inhaled nitric oxide on tracheal aspirate endothelin-1 levels in chronic lung disease of prematurity
    Truog, WE
    Ekekezie, II
    Kaftan, HA
    Castor, CA
    Norberg, M
    Thibeault, DW
    Clark, PL
    PEDIATRIC RESEARCH, 2000, 47 (04) : 378A - 378A